UBS lowered the firm’s price target on Bath & Body Works to $17 from $32 and keeps a Neutral rating on the shares. Bath & Body Works’ Q3 report is likely a negative catalyst for the stock, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Cautious Hold Rating for Bath & Body Works Amid Strategic Shifts and Underperformance
- Bath & Body Works price target lowered to $26 from $32 at BofA
- Bath & Body Works price target lowered to $25 from $33 at Wells Fargo
- Bath & Body Works price target lowered to $21 from $35 at Citi
- Bath & Body downgraded to Market Perform from Outperform at Telsey Advisory